Repository logo
 

Mesenchymal stem cell-extracellular vesicles deliver microRNAs that prevent nerve growth factor-induced sensory neuron sensitization

Accepted version
Peer-reviewed

Repository DOI


Change log

Abstract

Osteoarthritis (OA) affects 600 million individuals globally, pain being a hallmark symptom. Emerging clinical evidence supports the use of mesenchymal stem cells (MSCs) and their extracellular vesicles (MSC-EVs) for pain relief in knee OA. In mice, MSC-EVs ameliorate OA-induced pain and normalize knee-innervating neuron excitability. Moreover, it has been shown that overnight incubation of sensory neurons with MSC-EVs prevents the OA-associated mediator nerve growth factor (NGF) sensitizing sensory neurons. Here, conducting experiments with male and female C57BL/6J mice, we found that protease-mediated MSC-EV ‘shaving’ inhibited MSC-EV internalization into sensory neurons and the ability of MSC-EVs to prevent NGF-induced sensitization. In addition, acute, 10-minute, exposure of sensory neurons to MSC-EVs was also insufficient to counteract NGF. We hypothesized that MSC-EVs trigger transcriptional changes and found that inhibiting transcription prevented NGF-induced sensitization. MicroRNAs (miRNAs) can be delivered to cells by MSC-EVs, and certain miRNAs regulate transcription and pain; small RNA-sequencing of our MSC-EVs identified three candidate miRNAs, miR-21-5p, miR-148a-3p and miR-451a. Using gold nanoparticle delivery, each miRNA was able to prevent NGF sensitization of sensory neurons, a combination of all three showing the most pronounced effect. These findings demonstrate that MSC-EVs prevent NGF-induced sensory neuron sensitization via cellular uptake and transcriptional regulation that is mediated by miRNAs.

Description

Keywords

Journal Title

Journal of Neuroscience

Conference Name

Journal ISSN

0270-6474
1529-2401

Volume Title

Publisher

Society for Neuroscience

Publisher DOI

Publisher URL

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
MRC (MR/W002426/1)
Wellcome Trust (225856/Z/22/Z)
Arthritis Research UK (11600/21973)
From the paper: "This work was supported by the David James Trust Fund (LQ), Wellcome Trust (EStJS, 225856/Z/22/Z), a joint and equal investment from UKRI and Arthritis UK (EStJS, MR/W002426/1), and Arthritis UK (AC and EStJS, RG21973). "